Aradigm Gets Key Composition Of Matter Patents For Pulmaquin - Quick Facts

(RTTNews) - Aradigm Corp. (ARDM) said that the European Patent Office has issued an important new composition of matter patent entitled "Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile," to Aradigm for formulations of liposomal and free ciprofloxacin.

The company noted that the patent - E.U. Patent No. 2,079,443 - provides coverage for Aradigm's lead product candidate, the inhaled ciprofloxacin drug Pulmaquin, in Europe until at least October 23, 2027.

Further, Aradigm said it recently obtained its second patent in Australia entitled "Concentrated, Inhalable Ciprofloxacin Formulation," covering formulations of ciprofloxacin including that used in Pulmaquin. This patent will provide coverage until at least 2027.

In addition to these new patents in Europe and Australia, Aradigm has four issued U.S. patents and one issued Japanese patent which provide coverage for Pulmaquin in the U.S. until 2031 and in Japan until 2027.

Ciprofloxacin, available in oral and intravenous formulations, is a widely prescribed antibiotic. Pulmaquin is a dual release formulation composed of a mixture of liposome encapsulated and unencapsulated ciprofloxacin.